Epha Weight Loss Injection Trial Results and Launch Timeline
A new injectable obesity treatment called Epha demonstrated a mean weight loss of 9.02% over a 40-week clinical trial among Korean adults. Prescriptions for the drug are scheduled to begin around October 29.
Clinical Trial Weight Loss Efficacy and Participant Requirements
The phase 3 clinical trial evaluated 448 non-diabetic Korean adults who combined the injections with a daily 500-kilocalorie dietary reduction and at least 150 minutes of weekly exercise. Participants in the Epha treatment group achieved a 9.02% average weight reduction after 40 weeks, compared to an 0.89% reduction in the placebo group. Furthermore, 75.05% of participants receiving Epha lost 5% or more of their baseline body weight, versus 13.53% in the placebo group. An extension phase showed that participants maintained similar weight loss levels out to 64 weeks. Epha was approved as an adjunctive therapy alongside diet and exercise rather than a replacement for lifestyle modifications.
Reported Gastrointestinal Side Effects and Dose Escalation
Clinical data indicate that gastrointestinal side effects occur more frequently during the initial dose-escalation phase of treatment. These symptoms mirror the typical side effect profile reported for GLP-1 obesity injections. Medical guidance advises patients experiencing persistent or severe gastrointestinal issues to consult their prescribing physician rather than altering the dosage independently.
Frequently Asked Questions About Epha Prescriptions
When will Epha become available for patient prescriptions?
Prescriptions for the Epha weight loss injection are scheduled to begin around October 29 through clinical consultations.
What lifestyle changes are required during Epha treatment?
Trial participants combined the injections with a daily 500-kilocalorie reduction in their diet and a minimum of 150 minutes of weekly exercise.
How long did the primary Epha clinical trial last?
The primary phase 3 trial lasted for 40 weeks, followed by a 24-week extension period that tracked participants out to 64 weeks.
Related reading